Stemina Biomarker Discovery has pioneered building human cellular models for toxicity screening of drug candidates, chemical compounds, and cosmetic and tobacco ingredients. Our in vitro toxicity assays offer an alternative to animal tests that are highly predictive of human response using human cell-based endpoints and very little test compound. These assays can provide data in only a few weeks at a fraction of the cost of animal testing.
“[Stemina] provides a key platform in support of EPA’s ToxCast and Virtual Tissue Model programs, including an assay on human embryonic stem cell metabolism that is highly unique … as they specialize in metabolomics profiling. [Stemina] consistently exceeded performance expectations and successfully delivered timely, high-quality, responsive services and products.”
devTOX quickPredictTM is a biomarker-based, human, in vitro assay that predicts developmental toxicity. It utilizes key biomarkers identified using Stemina’s metabolomics platform.
Cardio quickPredictTM indicates the cardiotoxicity potential of drug candidates and other lead compounds based on changes in human induced pluripotent stem cell-derived cardiomyocyte (iPSC-CM) metabolism and viability.
The Results Are In!
Check out our recent publications….
Quantitative in vitro to in vivo extrapolation for developmental toxicity potency of valproic acid analogues [Birth Defects Research, May 2022]
microRNAs signatures as potential biomarkers of structural cardiotoxicity in human-induced pluripotent stem-cell derived cardiomyocytes [Organ Toxicity and Mechanisms, April 2022]
Use of human induced pluripotent stem cell-derived cardiomyocytes to predict the cardiotoxicity potential of Next Generation Nicotine Products [Frontiers in Toxicology, February 2022]
The use of human induced pluripotent stem cells to screen for developmental toxicity potential indicates reduced potential for non-combusted products, when compared to cigarettes [Current Research in Toxicology, November 2020]